No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SFM240719P85000
- 0.70
- -0.65-48.15%
15min DelayClose Jul 16 16:00 ET
0.75High0.57Low
0.65Open1.35Pre Close63 Volume127 Open Interest85.00Strike Price4.30KTurnover27.03%IV0.97%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.70Extrinsic Value100Contract SizeAmericanOptions Type-0.4635Delta0.1975Gamma117.42Leverage Ratio-0.1533Theta-0.0028Rho-54.43Eff Leverage0.0296Vega
Intraday
- 5D
- Daily
News
Express News | Evercore ISI Group Maintains In-Line on Sprouts Farmers Market, Raises Price Target to $80
Sprouts Farmers (SFM) Thrives on Product Innovation, Expansion
Sprouts Farmers Well Positioned To Gain Market Share In Various Macro Backdrops - Analyst Sees 'Solid Beat' In Q2
Goldman Sachs analyst Leah Jordan reiterated a Buy rating on Sprouts Farmers Market, Inc. (NASDAQ:SFM), raising the price forecast to $89 from $78 due to higher estimates.The company said it would
Goldman Sachs Adjusts Price Target on Sprouts Farmers Market to $89 From $78, Maintains Buy Rating
Sprouts Farmers Market (SFM) has an average hold rating and price target range of $40 to $94, according to analysts polled by Capital IQ.Price: 79.46, Change: -1.13, Percent Change: -1.40
Apple To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Goldman
Sprouts Farmers Market Is Maintained at Buy by Goldman Sachs
Sprouts Farmers Market Is Maintained at Buy by Goldman
Comments
Today, we are looking for targets to buy Mon. after Fri's massacre.
$Summit Therapeutics(SMMT.US$
Lung cancer Pharma company's new drug shows tangible improvement over the only other medication for the most common deadly case of lung cancer.
Fundamentals are solid. The PCB is overbought, though. We set our target for $13, but gonna watch this one close. Pharma be fickle.
$A10 Networks(ATEN.US$
I feel is strongest of the day. They make software for things like data-center optimization. Wonde...
$Summit Therapeutics(SMMT.US$
Lung cancer Pharma company's new drug shows tangible improvement over the only other medication for the most common deadly case of lung cancer.
Fundamentals are solid. The PCB is overbought, though. We set our target for $13, but gonna watch this one close. Pharma be fickle.
$A10 Networks(ATEN.US$
I feel is strongest of the day. They make software for things like data-center optimization. Wonde...
4
Investors' belief in Sprouts Farmers Market's continued market outperformance likely causes its high P/E ratio. However, with forecast growth only matching the wider market, the high P/E ratio may be unjustified, risking a share price decline. The current earnings growth level may also pressure the share price.
1
Significant insider selling at Sprouts Farmers Market may suggest insiders believe the shares are overpriced. Despite profitability and growth, the absence of insider buying and low insider ownership could caution potential investors.
Sprouts, a leading specialty grocer, has shown resilience despite grocery business challenges. Its quarterly performance was boosted by higher-than-anticipated same-store sales growth and fewer new store openings. The company's same-store sales growth and annual earnings forecast surpassed Wall Street's predictions. The stock rose 3.3% post-reporting.
1
The market's opinion of the business has improved over the past five years due to its growth track record. The stock's recent performance and strong share price momentum suggest it may be worth a closer look.
Read more